2023
DOI: 10.20944/preprints202306.1108.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Pharmaceutical Strategies to Make Better Drugs for Nonalcoholic Fatty Liver Disease Therapy

Abstract: Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible in the early stage without medical intervention, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, in the end, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors. Because of the complexity of the disease, the treatm… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 171 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?